Section Arrow
Quote
PRAX.NASDAQ
- Praxis Precision Medicines
Quotes are at least 15-min delayed:2025/09/12 00:05 EDT
Regular Hours
Last
 39.42
-0.81 (-2.01%)
Day High 
40.69 
Prev. Close
40.23 
1-M High
49.97 
Volume 
242.55K 
Bid
37.5
Ask
50.73
Day Low
39.4 
Open
40.46 
1-M Low
37.19 
Market Cap 
846.82M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 44.39 
20-SMA 45.72 
50-SMA 49.18 
52-W High 91.83 
52-W Low 26.7 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-12.40/-16.69
Enterprise Value
846.93M
Balance Sheet
Book Value Per Share
19.20
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
8.55M
Operating Revenue Per Share
0.09
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
GRIGRI Bio Inc.2.05+0.49+31.41%0.02PE
RXRXRecursion Pharmaceuticals4.85+0.31+6.83%-- 
SLXNSilexion Therapeutics Corp4.93+0.445+9.92%-- 
ADAPAdaptimmune Therapeutics plc0.0505-0.0003-0.59%-- 
ROIVRoivant Sciences Ltd14.41+0.64+4.65%1.95PE
Quotes are at least 15-min delayed：2025/09/12 00:05 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized bya neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.